Startups
zPREDICTA’s bio-simulation technology combines biology with automation and computation to provide end-to-end solution to fully automate drug development.
Addressing critical deficiencies in the accuracy, cost, and inhumane practices in drug development, zPREDICTA developed Reconstructed Organ (r-Organ™) bio-simulation platform that enables pharma to rapidly identify drug candidates that will be effective in patients.
r-Organ is a set of next generation 3D culture models that provide 1-to-1 reconstruction of human tissue microenvironment in an organ- and disease-specific manner allowing accurate prediction of drug response.
Utilizing r-Organ technology, zPREDICTA is building a proprietary multi-parameter data set to map cellular behavior in response to anticancer drugs.
zPREDICTA's r-Organ product lines, r-Bone™ and r-Lung™, cover multiple indications and are available in a kit format for blood (AML and multiple myeloma) and lung cancers. Additional models are also available by partnering with us.
Addressing critical deficiencies in the accuracy, cost, and inhumane practices in drug development, zPREDICTA developed Reconstructed Organ (r-Organ™) bio-simulation platform that enables pharma to rapidly identify drug candidates that will be effective in patients.
r-Organ is a set of next generation 3D culture models that provide 1-to-1 reconstruction of human tissue microenvironment in an organ- and disease-specific manner allowing accurate prediction of drug response.
Utilizing r-Organ technology, zPREDICTA is building a proprietary multi-parameter data set to map cellular behavior in response to anticancer drugs.
zPREDICTA's r-Organ product lines, r-Bone™ and r-Lung™, cover multiple indications and are available in a kit format for blood (AML and multiple myeloma) and lung cancers. Additional models are also available by partnering with us.
Overview
Location
United States, California, San Jose
Employees
1-10
Total raised
$100K
Founded date
2014
FAQ about zPREDICTA, a Predictive Oncology company
When was zPREDICTA, a Predictive Oncology company founded?
zPREDICTA, a Predictive Oncology company was founded in 2014.
How much funding has zPREDICTA, a Predictive Oncology company raised?
zPREDICTA, a Predictive Oncology company has raised $100K in total across 1 funding round.
Is zPREDICTA, a Predictive Oncology company still active?
Yes, zPREDICTA, a Predictive Oncology company is active.